Liposome Adjuvants: Simultaneous Induction of Innate and Adaptive Immunity is Key to Success
Journal Title: Journal of Vaccines and Immunology - Year 2015, Vol 1, Issue 1
Abstract
The current generation vaccines are mainly composed of highly purified antigens and tend to be poorly immunogenic, requiring potent adjuvants for their success. The adjuvants currently available suffer from various drawbacks such as low potency (inability to activate strong humoral and cell-mediated immune response) and extreme toxicity for routine clinical use in humans. In addition, not all adjuvants are effective for all antigens. The compromise between the requirement for strong adjuvant activity and an acceptable low level of toxicity has left us with limited choice of adjuvants. Although alum adjuvant has been used for decades, it is associated with severe local reaction and is unable to activate cell-mediated immunity, hence has proven unsuccessful against intracellular infections [1 1. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, et al. (1993) Adjuvants--a balance between toxicity and adjuvanticity. Vaccine 11: 293-306. ]. Therefore, it is very important to identify new adjuvants or improve the existing ones. The ideal adjuvant would be one that apart from activating strong humoral and cell-mediated immune response, has negligible toxicity to the host.
Authors and Affiliations
Faisal Syed M
Keywords
Related Articles
- EP ID EP553519
- DOI 10.17352/jvi.000004
- Views 62
- Downloads 0
Nanoparticles Vaccines Now and Future!
While the advanced use of effective vaccines has had an extraordinary impact on global health, there remain many diseases for which vaccines are not available. The concept of therapeutic infection vaccines is based on th...
Introduction of Stereo Chemical Constraints into β -Amino Acid Residues
Over the last 20 years, a large body of work in the literature has focused on the folded structures formed by peptide sequences containing backbone homologated residues. Currently increasing interest in peptide based vac...
Efficacy of a Recombinant Genotype VII Vaccine against Challenge with Velogenic Newcastle Disease Virus
Background: Newcastle disease virus (NDV) genotype VII has become the dominant genotype in China. However, NDV genotype II was used to make current commercial NDV vaccines. The mismatch of genotypes between circulating a...
Mammalian Parasitic Vaccine: A Consolidated Exposition
Parasites are highly prevalent in livestock worldwide and infect over one fourth of the human population also. Parasites are successful in evading host immune responses, and vaccination can prove to be an effective way t...
IMS 4112 and VLP of HBV as Th1 Adjuvants for a Recombinant Protein of HIV-1
Background: Current thinking suggests that vaccination approaches against the HIV-1 should be directed to elicit a Th1 cell-mediated immunity, neutralizing antibodies and/or ADCC mediating antibody responses. Also, exper...